Price (delayed)
$0.5382
Market cap
$14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$10.94M
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop
There are no recent dividends present for PTN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.